Eli Lilly Warns of Safety Risks with Compounded Tirzepatide
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 12 hours ago
0mins
Should l Buy LLY?
Source: seekingalpha
- Safety Risk Warning: Eli Lilly has issued a warning regarding compounded tirzepatide mixed with vitamin B12, revealing significant levels of impurities that could lead to toxicity and immune reactions, thus alerting patients to the potential dangers of using such products.
- FDA Recall Request: The company urged the FDA to recall all compounded tirzepatide products mixed with untested additives, emphasizing its commitment to consumer safety and the need to mitigate unknown risks associated with these medications.
- Competitive Market Pressure: Eli Lilly faces pressure from cheaper copycat versions of its drugs that bypass strict regulatory approval processes, despite the FDA declaring that the supply shortage has been resolved, meaning compounded medications are no longer permitted.
- Industry Dynamics Shift: Hims & Hers has entered into an agreement with Novo Nordisk to discontinue its compounded GLP-1 products in favor of Novo's weight-loss drugs, indicating a growing market preference for compliant products over unregulated alternatives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 999.840
Low
950.00
Averages
1192
High
1500
Current: 999.840
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Abivax Denies AstraZeneca Acquisition Talks
- Acquisition Rumor Denial: Abivax has denied media reports claiming that AstraZeneca was in talks to acquire the company, despite the report stating that AstraZeneca had exclusive access to Abivax's data since February and had until March 23 to formalize an offer.
- Stock Price Fluctuation: Following the report, Abivax's shares surged by as much as 15%, but ultimately closed about 4% higher, indicating a cautious market reaction to the acquisition rumors.
- Potential Acquisition Interest: Analysts suggest that Abivax's immunology and inflammation drug obefazimod could attract large pharmaceutical companies for acquisition, especially after its strong performance in last year's late-stage trials, enhancing its strategic value.
- Competitor Attention: In addition to AstraZeneca, Eli Lilly has also been rumored to be in talks with Abivax regarding a potential acquisition, although both companies have declined to comment, reflecting strong market interest in Abivax.
See More
S&P 500 Healthcare Holdings Growth Factor Grades Analysis
- Healthcare Growth Ratings: The S&P 500 healthcare sector has faced turbulence, with Eli Lilly (LLY) leading with an A grade, indicating strong growth potential that may attract investor interest.
- Sector Rotation Trends: Amid escalating geopolitical tensions, investors are shifting towards defensive stocks, resulting in technical deterioration for healthcare stocks, which impacts overall market sentiment.
- Low Growth Rated Companies: Companies like Thermo Fisher (TMO), Abbott (ABT), and Merck (MRK) received D- grades, indicating they face growth challenges in the current market environment, potentially affecting their stock performance.
- Rating Impact Analysis: Growth factor grades serve as a crucial metric for assessing a company's expansion potential, with Eli Lilly's A rating starkly contrasting with other lower-rated companies, likely prompting investors to reassess their portfolio allocations.
See More
Eli Lilly Warns of Safety Risks in Compounded Tirzepatide Products
- Safety Risk Warning: Eli Lilly issued a warning regarding compounded tirzepatide products mixed with vitamin B12, as internal testing revealed a new impurity that may pose unknown health risks, emphasizing that the drug has never been studied in combination with vitamin B12, potentially affecting its interaction with GLP-1 and GIP receptors.
- Regulatory Issues with Compounded Drugs: The company noted that pharmacies producing compounded versions are not required to track or report adverse events like FDA-approved manufacturers, which may expose patients to potentially dangerous treatments, especially those obtained through telehealth platforms or medical spas.
- Criticism of Mass Compounding: Lilly reiterated concerns about mass-compounded versions of its tirzepatide medicines, supporting FDA actions to curb the distribution of compounded anti-obesity drugs that violate regulatory standards, arguing that many compounded products are not customized for individual patients.
- Potential Additional Risks: Beyond vitamin B12, Lilly identified other substances mixed with tirzepatide, such as glycine and carnitine, which could introduce untested combinations, and reported additional safety issues including bacterial contamination and elevated endotoxin levels, urging the FDA to consider recalls of compounded products containing untested additives.
See More
Pfizer Stock Shows Signs of Reversal Potential
- Technical Reversal Signals: Pfizer's stock has formed a series of higher lows over the past year, breaking above its downtrend since the 2024 peak, indicating potential for a reversal that may provide investors with a timely re-entry opportunity.
- Defined Support Levels: The stock's downside support is clearly defined around the rising 50-day moving average, forming an ascending triangle with a breakout target of $30.50, suggesting a favorable risk/reward scenario in the current market environment.
- Improving Momentum Indicators: The Relative Strength Index (RSI) is trending higher and not overbought, indicating enhanced buying momentum, allowing investors to consider buying on recent weakness to capitalize on a potential rally above $27.50 towards $30.
- Safe Dividend Yield: With a current dividend yield of 6.4%, Pfizer, as part of the large pharma sector, may serve as a safe haven for investors amid increasing market volatility, providing stable returns with relatively low risk.
See More
Midday Stock Highlights: Notable Movements in Multiple Stocks
- Market Decline: Mercado Libre's shares fell over 6% after JPMorgan downgraded its rating from overweight to neutral, citing increased competition and prolonged margin pressures, with the price target cut from $2,650 to $2,100, indicating concerns about future profitability.
- Cruise Industry Pressure: Shares of Royal Caribbean and Carnival dropped 5% and 6%, respectively, as oil prices surged past $100 per barrel, with fuel being one of the largest operating expenses for cruise operators, potentially impacting their profitability.
- Energy Stocks Rise: Constellation Energy and Vistra saw their shares increase by 2% following the Department of Energy's announcement of a plan to leverage existing nuclear energy infrastructure for increased power generation, highlighting the strategic importance of nuclear energy for future growth.
- Pet Health Surge: Petco Health and Wellness shares surged nearly 30% after the company indicated a potential return to sales growth, guiding for full-year revenue growth between flat and 1.5%, exceeding market expectations and reflecting confidence in its business recovery.
See More
Major Averages Decline Amid Oil Price Volatility
- Market Impact from Oil Prices: The major averages, including the Dow, fell over 400 points as oil prices surged above $100 earlier in the week, reflecting traders' concerns over volatile energy prices and geopolitical tensions in the Middle East.
- IEA's Strategic Release: The International Energy Agency's decision to release approximately 400 million barrels from strategic reserves aims to stabilize energy markets following supply shocks due to conflicts, which could help mitigate extreme oil price fluctuations.
- Inflation Data Reaction: Recent inflation data showed a 0.3% month-over-month increase in the consumer price index and a 2.4% year-over-year rise, both aligning with consensus expectations, indicating persistent inflationary pressures that may influence future monetary policy decisions.
- Escalating Geopolitical Risks: U.S. forces sunk several Iranian ships near the Strait of Hormuz, heightening the fragility of global energy supply routes and contributing to unstable market sentiment, prompting investors to adopt a cautious stance regarding future market movements.
See More
Abivax Denies AstraZeneca Acquisition Talks
- Acquisition Rumor Denial: Abivax has denied media reports claiming that AstraZeneca was in talks to acquire the company, despite the report stating that AstraZeneca had exclusive access to Abivax's data since February and had until March 23 to formalize an offer.
- Stock Price Fluctuation: Following the report, Abivax's shares surged by as much as 15%, but ultimately closed about 4% higher, indicating a cautious market reaction to the acquisition rumors.
- Potential Acquisition Interest: Analysts suggest that Abivax's immunology and inflammation drug obefazimod could attract large pharmaceutical companies for acquisition, especially after its strong performance in last year's late-stage trials, enhancing its strategic value.
- Competitor Attention: In addition to AstraZeneca, Eli Lilly has also been rumored to be in talks with Abivax regarding a potential acquisition, although both companies have declined to comment, reflecting strong market interest in Abivax.
See More
S&P 500 Healthcare Holdings Growth Factor Grades Analysis
- Healthcare Growth Ratings: The S&P 500 healthcare sector has faced turbulence, with Eli Lilly (LLY) leading with an A grade, indicating strong growth potential that may attract investor interest.
- Sector Rotation Trends: Amid escalating geopolitical tensions, investors are shifting towards defensive stocks, resulting in technical deterioration for healthcare stocks, which impacts overall market sentiment.
- Low Growth Rated Companies: Companies like Thermo Fisher (TMO), Abbott (ABT), and Merck (MRK) received D- grades, indicating they face growth challenges in the current market environment, potentially affecting their stock performance.
- Rating Impact Analysis: Growth factor grades serve as a crucial metric for assessing a company's expansion potential, with Eli Lilly's A rating starkly contrasting with other lower-rated companies, likely prompting investors to reassess their portfolio allocations.
See More
Eli Lilly Warns of Safety Risks in Compounded Tirzepatide Products
- Safety Risk Warning: Eli Lilly issued a warning regarding compounded tirzepatide products mixed with vitamin B12, as internal testing revealed a new impurity that may pose unknown health risks, emphasizing that the drug has never been studied in combination with vitamin B12, potentially affecting its interaction with GLP-1 and GIP receptors.
- Regulatory Issues with Compounded Drugs: The company noted that pharmacies producing compounded versions are not required to track or report adverse events like FDA-approved manufacturers, which may expose patients to potentially dangerous treatments, especially those obtained through telehealth platforms or medical spas.
- Criticism of Mass Compounding: Lilly reiterated concerns about mass-compounded versions of its tirzepatide medicines, supporting FDA actions to curb the distribution of compounded anti-obesity drugs that violate regulatory standards, arguing that many compounded products are not customized for individual patients.
- Potential Additional Risks: Beyond vitamin B12, Lilly identified other substances mixed with tirzepatide, such as glycine and carnitine, which could introduce untested combinations, and reported additional safety issues including bacterial contamination and elevated endotoxin levels, urging the FDA to consider recalls of compounded products containing untested additives.
See More
Pfizer Stock Shows Signs of Reversal Potential
- Technical Reversal Signals: Pfizer's stock has formed a series of higher lows over the past year, breaking above its downtrend since the 2024 peak, indicating potential for a reversal that may provide investors with a timely re-entry opportunity.
- Defined Support Levels: The stock's downside support is clearly defined around the rising 50-day moving average, forming an ascending triangle with a breakout target of $30.50, suggesting a favorable risk/reward scenario in the current market environment.
- Improving Momentum Indicators: The Relative Strength Index (RSI) is trending higher and not overbought, indicating enhanced buying momentum, allowing investors to consider buying on recent weakness to capitalize on a potential rally above $27.50 towards $30.
- Safe Dividend Yield: With a current dividend yield of 6.4%, Pfizer, as part of the large pharma sector, may serve as a safe haven for investors amid increasing market volatility, providing stable returns with relatively low risk.
See More
Midday Stock Highlights: Notable Movements in Multiple Stocks
- Market Decline: Mercado Libre's shares fell over 6% after JPMorgan downgraded its rating from overweight to neutral, citing increased competition and prolonged margin pressures, with the price target cut from $2,650 to $2,100, indicating concerns about future profitability.
- Cruise Industry Pressure: Shares of Royal Caribbean and Carnival dropped 5% and 6%, respectively, as oil prices surged past $100 per barrel, with fuel being one of the largest operating expenses for cruise operators, potentially impacting their profitability.
- Energy Stocks Rise: Constellation Energy and Vistra saw their shares increase by 2% following the Department of Energy's announcement of a plan to leverage existing nuclear energy infrastructure for increased power generation, highlighting the strategic importance of nuclear energy for future growth.
- Pet Health Surge: Petco Health and Wellness shares surged nearly 30% after the company indicated a potential return to sales growth, guiding for full-year revenue growth between flat and 1.5%, exceeding market expectations and reflecting confidence in its business recovery.
See More
Major Averages Decline Amid Oil Price Volatility
- Market Impact from Oil Prices: The major averages, including the Dow, fell over 400 points as oil prices surged above $100 earlier in the week, reflecting traders' concerns over volatile energy prices and geopolitical tensions in the Middle East.
- IEA's Strategic Release: The International Energy Agency's decision to release approximately 400 million barrels from strategic reserves aims to stabilize energy markets following supply shocks due to conflicts, which could help mitigate extreme oil price fluctuations.
- Inflation Data Reaction: Recent inflation data showed a 0.3% month-over-month increase in the consumer price index and a 2.4% year-over-year rise, both aligning with consensus expectations, indicating persistent inflationary pressures that may influence future monetary policy decisions.
- Escalating Geopolitical Risks: U.S. forces sunk several Iranian ships near the Strait of Hormuz, heightening the fragility of global energy supply routes and contributing to unstable market sentiment, prompting investors to adopt a cautious stance regarding future market movements.
See More
